eligibility_summary
Eligibility: Multiple myeloma per IMWG with measurable disease (serum M≥0.5 g/dL, urine M≥200 mg/24h, or FLC≥10 mg/dL with abnormal ratio), relapsed/refractory with PD or ≤minimal response to last regimen, ECOG 0–2, not pregnant or breastfeeding during treatment and 6 months after. Exclude: study-drug hypersensitivity, stroke/TIA/seizure ≤6 mo, major surgery/trauma ≤2 wks or not recovered/planned, ≥140 mg prednisone eq in 14 days pre-dose, active CNS/meningeal MM (MRI/CSF if suspected).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3 RRMM trial comparing: 1) Talquetamab + pomalidomide, 2) Talquetamab + teclistamab, vs 3) EPd (elotuzumab+pomalidomide+dexamethasone) or PVd (pomalidomide+bortezomib+dexamethasone). Mechanisms/types: Talquetamab is a GPRC5D×CD3 bispecific T‑cell–engaging antibody (SC) redirecting CD3+ T cells to kill GPRC5D+ myeloma cells, Teclistamab is a BCMA×CD3 bispecific antibody (SC) inducing T‑cell cytotoxicity of BCMA+ plasma cells, Pomalidomide is an IMiD/CRBN modulator (oral) degrading IKZF1/3, enhancing T/NK activity, Elotuzumab is an anti‑SLAMF7 mAb (IV) activating NK cells and mediating ADCC on SLAMF7+ myeloma, Bortezomib is a proteasome inhibitor (SC) blocking β5/26S proteasome and NF‑κB, inducing apoptosis, Dexamethasone is a glucocorticoid (oral/IV). Targets/pathways: GPRC5D, BCMA, SLAMF7 on myeloma, CD3 T cells, NK cells, cereblon/IKZF1/3, proteasome/NF‑κB, glucocorticoid receptor.